Aethlon Medical (NASDAQ:AEMD) Stock Price Crosses Below 200-Day Moving Average – Here’s Why

Aethlon Medical, Inc. (NASDAQ:AEMD) crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.99 and traded as low as $0.59. Aethlon Medical shares last traded at $0.6005, with a volume of 44,648 shares.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Aethlon Medical in a report on Friday, July 17th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Reduce”.

Aethlon Medical Trading Up 1.4%

The firm has a market capitalization of $1.42 million, a PE ratio of -0.04 and a beta of 1.41. The business has a fifty day moving average price of $1.49 and a two-hundred day moving average price of $1.99.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Aethlon Medical stock. Citadel Advisors LLC purchased a new stake in shares of Aethlon Medical, Inc. (NASDAQ:AEMD) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned about 36.57% of Aethlon Medical at the end of the most recent reporting period. Institutional investors own 1.99% of the company’s stock.

Aethlon Medical Company Profile

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.